{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-291979","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2025-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.431589+00:00","generated_at":"2026-05-16T17:29:03.873814+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lineage achieves first OpRegen milestone under Roche deal; $5M payment triggered","bullets":["First development milestone under Roche Agreement for OpRegen (RG6501) achieved; $5M payment triggered.","Payment expected within 30 days; net proceeds after ~24.1% to Israel Innovation Authority and ~21.5% to Hadasit.","OpRegen is being evaluated in Phase 2a GAlette trial for geographic atrophy secondary to AMD.","Milestone based on manufacturing and clinical advancements in the OpRegen cell therapy program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-291979","json":"https://secwatch.observer/filing/0001193125-25-291979.json","markdown":"https://secwatch.observer/filing/0001193125-25-291979.md","text":"https://secwatch.observer/filing/0001193125-25-291979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000119312525291979/0001193125-25-291979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000119312525291979/lctx-20251120.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:29:03.873814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}